Zhejiang NHU Valuation Multiples

Zhejiang NHU Overview

About Zhejiang NHU

Zhejiang Nhu Co Ltd is a China-based company engaged in the manufacture and sales of pharmaceuticals, health protection products, pharmaceutical intermediates, fragrances, food additives, and feed additives. The company's active pharmaceutical ingredient products cover various areas such as Cardiovascular, Anti-AIDS, Anti-cancer, and Anti-bacterial, with key products such as Latamoxef Sodium, Flomoxef Sodium, Hydrochloride Moxifloxacin, Artemisinin series, Calcium Keto acid series, Vitamin A/E/D3, and coenzyme Q10, and others. The other business areas are Aroma chemicals, Polymers, and Nutrition. The organization markets its products in China and internationally.

Founded

1994

HQ

Employees

11.4K

Website

cnhu.com

Sectors

Nutraceuticals & CosmeceuticalsBioindustrialsBioTech

Financials (LTM)

Revenue: $3B

EBITDA: $2B

EV

$16B

Valuation Multiples

Multiples.vc

Start free trial

Zhejiang NHU Financials

Zhejiang NHU reported last 12-month revenue of $3B and EBITDA of $2B.

In the same LTM period, Zhejiang NHU generated $2B in gross profit, $2B in EBITDA, and $1B in net income.

Zhejiang NHU P&L

In the most recent fiscal year, Zhejiang NHU reported revenue of $3B and EBITDA of $2B.

Zhejiang NHU expects next 12-month revenue of XXX and NTM EBITDA of XXX

Zhejiang NHU Stock Performance

Zhejiang NHU has current market cap of $16B, and enterprise value of $16B.

Zhejiang NHU's stock price is $5.31.

Zhejiang NHU Valuation Multiples

Zhejiang NHU trades at 4.7x EV/Revenue multiple, and 10.5x EV/EBITDA.

Zhejiang NHU Financial Valuation Multiples

As of April 19, 2026, Zhejiang NHU has market cap of $16B and EV of $16B.

Equity research analysts estimate Zhejiang NHU's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Zhejiang NHU has a P/E ratio of 15.7x.

Zhejiang NHU Margins & Growth Rates

Zhejiang NHU's revenue in the last 12 month grew by 11%.

Zhejiang NHU's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.0M for the same period.

Zhejiang NHU's rule of 40 is 58% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Zhejiang NHU's rule of X is 79% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Zhejiang NHU Public Comps

See public comps and valuation multiples for other Nutraceuticals & Cosmeceuticals and Bioindustrials comps.

Zhejiang NHU M&A Activity

Zhejiang NHU acquired XXX companies to date.

Last acquisition by Zhejiang NHU was on XXXXXXXX, XXXXX. Zhejiang NHU acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Zhejiang NHU Investment Activity

Zhejiang NHU invested in XXX companies to date.

Zhejiang NHU made its latest investment on XXXXXXXX, XXXXX. Zhejiang NHU invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).